Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug

Journal of Clinical Microbiology

Volumn 47, Issue 9, 2009, Pages 3064-3065

  Zavascki, Alexandre P ^a   Li, Jian ^b   Nation, Roger L ^b   Superti, Silvana V ^c   Barth, Afonso L ^a   Lutz, Larissa ^a   Ramos, Fabiano ^c   Boniatti, Márcio M ^a   Goldani, Luciano Z ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b MONASH UNIVERSITY   (Australia)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; POLYMYXIN B; RESTRICTION ENDONUCLEASE; VANCOMYCIN;

ACINETOBACTER; ADULT; AGAR DILUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BRONCHUS SECRETION; CLINICAL ARTICLE; CREATININE CLEARANCE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; TRACHEAL ASPIRATION PROCEDURE; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ACINETOBACTER; PSEUDOMONAS AERUGINOSA;

EID: 69949084464     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01035-09     Document Type: Letter

References (9)

1. American Thoracic Society; Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
2. Bergen, P. J., J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne. 2008. Comparison of once-, twice-, and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa and an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Lee, J., G. Patel, S. Huprikar, D. P. Calfee, and S. G. Jenkins. 2009. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47:1611-1612.
5. Poudyal, A., B. P. Howden, J. M. Bell, W. Gao, R. J. Owen, J. D. Turnidge, R. L. Nation, and J. Li. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62:1311-1318.
6. Tan, C. H., J. Li, and R. L. Nation. 2007. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmcodynamic model. Antimicrob. Agents Chemother. 51:3413-3415.
7. Zavascki, A. P., and J. Li. 2008. Intravenous colistimethate for multidrugresistant Gram-negative bacteria. Lancet Infect. Dis. 8:403-405.
8. Zavascki, A. P., L. Z. Goldani, G. Cao, S. V. Superti, L. Lutz, A. L. Barth, F. Ramos, M. M. Boniatti, J. Li, and R. L. Nation. 2008. Pharmacokinetics of intravenous polymyxin B in critically-ill patients. Clin. Infect. Dis. 47:1298-1304.
9. Zavascki, A. P., L. Z. Goldani, R. L. Nation, and J. Li. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60:1206-1215.